233 related articles for article (PubMed ID: 15709173)
1. Expression of the FOXP1 transcription factor is strongly associated with inferior survival in patients with diffuse large B-cell lymphoma.
Banham AH; Connors JM; Brown PJ; Cordell JL; Ott G; Sreenivasan G; Farinha P; Horsman DE; Gascoyne RD
Clin Cancer Res; 2005 Feb; 11(3):1065-72. PubMed ID: 15709173
[TBL] [Abstract][Full Text] [Related]
2. Forkhead box protein P1 expression in mucosa-associated lymphoid tissue lymphomas predicts poor prognosis and transformation to diffuse large B-cell lymphoma.
Sagaert X; de Paepe P; Libbrecht L; Vanhentenrijk V; Verhoef G; Thomas J; Wlodarska I; De Wolf-Peeters C
J Clin Oncol; 2006 Jun; 24(16):2490-7. PubMed ID: 16636337
[TBL] [Abstract][Full Text] [Related]
3. Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas.
Nyman H; Jerkeman M; Karjalainen-Lindsberg ML; Banham AH; Enblad G; Leppä S
Eur J Haematol; 2009 May; 82(5):364-72. PubMed ID: 19141121
[TBL] [Abstract][Full Text] [Related]
4. FOXP1 protein overexpression is associated with inferior outcome in nodal diffuse large B-cell lymphomas with non-germinal centre phenotype, independent of gains and structural aberrations at 3p14.1.
Hoeller S; Schneider A; Haralambieva E; Dirnhofer S; Tzankov A
Histopathology; 2010 Jul; 57(1):73-80. PubMed ID: 20579129
[TBL] [Abstract][Full Text] [Related]
5. Diffuse large B-cell lymphoma with overexpression of cyclin e substantiates poor standard treatment response and inferior outcome.
Tzankov A; Gschwendtner A; Augustin F; Fiegl M; Obermann EC; Dirnhofer S; Went P
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2125-32. PubMed ID: 16609025
[TBL] [Abstract][Full Text] [Related]
6. FOXP1 expression and its clinicopathologic significance in nodal and extranodal diffuse large B-cell lymphoma.
Yu B; Zhou X; Li B; Xiao X; Yan S; Shi D
Ann Hematol; 2011 Jun; 90(6):701-8. PubMed ID: 21120478
[TBL] [Abstract][Full Text] [Related]
7. Preferential expression of truncated isoforms of FOXP1 in primary central nervous system lymphoma.
Courts C; Brunn A; Montesinos-Rongen M; Siemer D; Hans V; Paulus W; Wiestler OD; Küppers R; Siebert R; Deckert M
J Neuropathol Exp Neurol; 2009 Sep; 68(9):972-6. PubMed ID: 19680146
[TBL] [Abstract][Full Text] [Related]
8. The FOXP1 winged helix transcription factor is a novel candidate tumor suppressor gene on chromosome 3p.
Banham AH; Beasley N; Campo E; Fernandez PL; Fidler C; Gatter K; Jones M; Mason DY; Prime JE; Trougouboff P; Wood K; Cordell JL
Cancer Res; 2001 Dec; 61(24):8820-9. PubMed ID: 11751404
[TBL] [Abstract][Full Text] [Related]
9. t(3;14)(p14;q32) results in aberrant expression of FOXP1 in a case of diffuse large B-cell lymphoma.
Fenton JA; Schuuring E; Barrans SL; Banham AH; Rollinson SJ; Morgan GJ; Jack AS; van Krieken JH; Kluin PM
Genes Chromosomes Cancer; 2006 Feb; 45(2):164-8. PubMed ID: 16252263
[TBL] [Abstract][Full Text] [Related]
10. Membrane PKC-beta 2 protein expression predicts for poor response to chemotherapy and survival in patients with diffuse large B-cell lymphoma.
Espinosa I; Briones J; Bordes R; Brunet S; Martino R; Sureda A; Prat J; Sierra J
Ann Hematol; 2006 Sep; 85(9):597-603. PubMed ID: 16830142
[TBL] [Abstract][Full Text] [Related]
11. Both FOXP1 and p65 expression are adverse risk factors in diffuse large B-cell lymphoma: a retrospective study in China.
Hu CR; Wang JH; Wang R; Sun Q; Chen LB
Acta Histochem; 2013 Mar; 115(2):137-43. PubMed ID: 22809882
[TBL] [Abstract][Full Text] [Related]
12. Cyclin B1 expression is an independent prognostic marker for poor outcome in diffuse large B-cell lymphoma.
Obermann EC; Went P; Pehrs AC; Tzankov A; Wild PJ; Pileri S; Hofstaedter F; Dirnhofer S
Oncol Rep; 2005 Dec; 14(6):1461-7. PubMed ID: 16273239
[TBL] [Abstract][Full Text] [Related]
13. Cyclin D3 is a predictive and prognostic factor in diffuse large B-cell lymphoma.
Filipits M; Jaeger U; Pohl G; Stranzl T; Simonitsch I; Kaider A; Skrabs C; Pirker R
Clin Cancer Res; 2002 Mar; 8(3):729-33. PubMed ID: 11895902
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical expression of CD23 and CD40 may identify prognostically favorable subgroups of diffuse large B-cell lymphoma: a Nordic Lymphoma Group Study.
Linderoth J; Jerkeman M; Cavallin-Ståhl E; Kvaløy S; Torlakovic E;
Clin Cancer Res; 2003 Feb; 9(2):722-8. PubMed ID: 12576441
[TBL] [Abstract][Full Text] [Related]
15. CD21S antigen expression in tumour cells of diffuse large B-cell lymphomas is an independent prognostic factor indicating better overall survival.
Ogawa S; Yamaguchi M; Oka K; Taniguchi M; Ito M; Nishii K; Nakase K; Ohno T; Kita K; Kobayashi T; Shiku H
Br J Haematol; 2004 Apr; 125(2):180-6. PubMed ID: 15059140
[TBL] [Abstract][Full Text] [Related]
16. LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab.
Natkunam Y; Farinha P; Hsi ED; Hans CP; Tibshirani R; Sehn LH; Connors JM; Gratzinger D; Rosado M; Zhao S; Pohlman B; Wongchaowart N; Bast M; Avigdor A; Schiby G; Nagler A; Byrne GE; Levy R; Gascoyne RD; Lossos IS
J Clin Oncol; 2008 Jan; 26(3):447-54. PubMed ID: 18086797
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma.
Muris JJ; Meijer CJ; Vos W; van Krieken JH; Jiwa NM; Ossenkoppele GJ; Oudejans JJ
J Pathol; 2006 Apr; 208(5):714-23. PubMed ID: 16400625
[TBL] [Abstract][Full Text] [Related]
18. Expression of survivin and of antigen detected by a novel monoclonal antibody, T332, is associated with outcome of diffuse large B-cell lymphoma and its subtypes.
Watanuki-Miyauchi R; Kojima Y; Tsurumi H; Hara T; Goto N; Kasahara S; Saio M; Moriwaki H; Takami T
Pathol Int; 2005 Jun; 55(6):324-30. PubMed ID: 15943789
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of BACH2 expression in diffuse large B-cell lymphoma: a study of the Osaka Lymphoma Study Group.
Sakane-Ishikawa E; Nakatsuka S; Tomita Y; Fujita S; Nakamichi I; Takakuwa T; Sugiyama H; Fukuhara S; Hino M; Kanamaru A; Soma T; Tsukaguchi M; Igarashi K; Kanakura Y; Aozasa K;
J Clin Oncol; 2005 Nov; 23(31):8012-7. PubMed ID: 16258099
[TBL] [Abstract][Full Text] [Related]
20. Translocations involving the immunoglobulin heavy chain gene locus predict better survival in gastric diffuse large B-cell lymphoma.
Nakamura S; Ye H; Bacon CM; Goatly A; Liu H; Kerr L; Banham AH; Streubel B; Yao T; Tsuneyoshi M; Savio A; Takeshita M; Dartigues P; Ruskoné-Fourmestraux A; Matsumoto T; Iida M; Du MQ
Clin Cancer Res; 2008 May; 14(10):3002-10. PubMed ID: 18445693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
